-
The clinical trial application of BPI-16350 drug combination treatment of breast cancer by Betta Pharmaceuticals has been accepted
Time of Update: 2021-04-19
The company declared that BPI-16350 capsules combined with fulvestrant or aromatase inhibitors were used to treat breast cancer.
BPI-16350 was approved by the Drug Evaluation Center in 2018, and clinical trials of a single drug for advanced solid tumors have been carried out, and the phase I clinical research is currently in progress.
-
Targeting Claudin 18.2 and 4-1BB!
Time of Update: 2021-04-19
2, TJ-CD4B can still bind to tumor cells and produce better immune activity than other 4-1BB monoclonal antibodies, making it expected to be suitable for a wider range of patients group.
-
Fuhong Henlius plans to submit a listing application for phase 2 clinical trial of anti-PD-1 antibody reaching the primary endpoint
Time of Update: 2021-04-19
The primary endpoint reached this time is a single-arm, open, multiple-arm, open-ended, multiple-arm, open-ended, multiple-arm, unresectable or metastatic MSI-H or dMMR solid tumor patient who has failed standard treatments to evaluate the efficacy, safety, and tolerability of HLX10.
-
Hengrui Medicine SHR8008 capsules and HRS2543 tablets were approved for clinical trials
Time of Update: 2021-04-19
After inquiries, at present, fluconazole, itraconazole, voriconazole and isaconazole and other similar products of SHR8008 have been approved for marketing at home and abroad.
Voriconazole was developed by Pfizer and was approved for marketing in the United States in 2002.
-
The National Health and Medical Commission's Medical Management Bureau issued the "Long-term Prescription Management Standards"
Time of Update: 2021-04-19
Chapter 5 Long-term prescription drug management Article 26 Primary medical and health institutions shall include the long-term prescription information issued by the institution in the patient's health file, and record the patient's diagnosis and treatment and medication records in detail.
-
The 6.5 billion market welcomes the impact: Howson, Better, Dongyang...
Time of Update: 2021-04-18
414 ，、“”，。，4，，？，1，？，。 20，1 1：2020 ： ，2020，20%，，，9%，65。，，，？ 1：2021（） ：MED2. 0 Since 2021, a total of 20 new antithrombotic drugs (according to product name + company statistics) have been approve
-
National Medical Insurance Administration: 24 billion prepaid funds guarantee free vaccination
Time of Update: 2021-04-18
On April 14, my country's new crown pneumonia vaccination was based on the principle of voluntary vaccinations by individuals and free of charge by the state. As of April 11, a total of 16,7343,000 d
-
The legal representative of a pharmaceutical company was investigated on suspicion of bribery
Time of Update: 2021-04-18
On April 10, the website of the State Supervision Commission of the Central Commission for Discipline Inspection found that Dai Longyong, the legal representative of Jiangxi Yongchang Pharmaceutical Co.
-
The start of the second batch of consumables collection in Fujian involves 7 categories such as pacemakers and coronary balloons
Time of Update: 2021-04-18
Enterprise proposed to be selected ① 1 set of hemorrhoid stapler (the total purchase quantity of the same enterprise accounts for ≥5% ) The first round: Except for the one company with the lowest weighted quotation in this group, the two companies that ranked the bottom two in decline are eliminated, and the remaining companies enter the second round.
-
The salary of the CEO of the new crown vaccine manufacturer has soared!
Time of Update: 2021-04-18
The foreign media BioSpace website pays attention to the annual salary of vaccine developer CEO:Pfizer: Albert BourlaPfizer: Albert BourlaPfizer CEO Bora will make a net profit of US$21 million in 2020 because his company has cooperated with German BioNTech and became the first company to obtain emergency use authorization for the COVID-19 vaccine in the United States.
-
Pfizer abrocitinib and Xeljanz review delayed by FDA for 3 months
Time of Update: 2021-04-18
In addition, the FDA has extended the review period of the supplementary new drug application (sNDA) for the oral anti-inflammatory drug Xeljanz/Xeljanz XR (tofacitinib, tofacitinib) for the treatment of adult patients with active ankylosing spondylitis (AS) by 3 months.
-
Junshi PD-1 urothelial cancer indication is officially approved
Time of Update: 2021-04-18
The marketing application for this new indication is based on the POLARIS-03 study (NCT03113266), which is an open, single-arm, multi-center, phase II key registration clinical study, which aims to evaluate the failure of standard treatment of teriprizumab Safety and effectiveness in patients with locally advanced or metastatic bladder urothelial cancer.
-
Takeda's treatment drug Feizeyou for acute hereditary angioedema episodes is approved to protect the lives of Chinese HAE patients
Time of Update: 2021-04-18
April 8, 2021, Shanghai — Takeda China announced that Feizeyou® (icatibant acetate injection) has been officially approved by the National Medical Products Administration for the treatment of heredity in adults, adolescents and children ≥2 years of age Acute onset of angioedema (HAE).
-
The state takes action! The medical insurance reform that benefits more than 300 million employees will usher in a big move
Time of Update: 2021-04-18
Medical Network, April 9 News On April 7, Chinese Premier Li Keqiang presided over an executive meeting of the State Council to determine measures to establish and improve the basic medical insurance outpatient mutual aid guarantee mechanism for employees, broaden the use of personal account funds, and reduce the medical burden of the masses.
-
Yuandong Biology is showing its power!
Time of Update: 2021-04-18
com, in 2019, the sales of Dabigatran Etexilate Capsules in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan, a year-on-year increase of 39.
-
China National Institute of Biological Sciences of Sinopharm Group's recombinant new coronavirus vaccine approved for clinical trials
Time of Update: 2021-04-18
China Biotech stated that the genetic recombinant protein vaccine has a mature technology route and is suitable for large-scale production.
-
Huahai Pharmaceutical: Q1 deduction of non-net profit pre-cut by 15%-25%, unable to judge the impact of the valsartan incident
Time of Update: 2021-04-18
At the same time, in the first quarter of 2021, the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses has declined, mainly due to changes in the sales structure of API products, the continued impact of the FDA ban on the preparations business in the United States, and the company's continuous increase in R&D investment.
-
Official support!
Time of Update: 2021-04-18
Online prescription drugs welcome breakthrough Hainan established the country's first independent construction and operation electronic prescription center The "Special Measures" proposes to support the development of Internet prescription drug sales.
-
Xinjiang’s “2+4” Drug Purchasing Alliance Came to Promote Inter-provincial Centralized Procurement
Time of Update: 2021-04-18
The pace is accelerating, and another inter-provincial alliance brings a lot of purchases Xinjiang "2+4 " alliance is here On April 12, the Xinjiang Medical Insurance Bureau issued an announcement on publicly soliciting opinions and suggestions on the "2+4" Alliance of Xinjiang Production and Construction Corps of Xinjiang Uygur Autonomous Region to organize centralized drug procurement and use of drugs (draft for comments).
-
my country’s first case of “serious” dishonesty related drugs was suspended for online trading
Time of Update: 2021-04-18
cn/news/yyzb/" target="_blank"> procurement procurement In August 2020, the National Medical Insurance Administration launched the construction of a medical price and credit evaluation system, and gave rebates and other outstanding issues in the medical field to give play to the guiding and standardizing role of the centralized procurement market for medical products, and promote the return of reasonable prices of medical products.
